Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. urinary tract
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • This Year
  • Older

Urinary Tract Articles & Analysis

44 news found

Protein fractionation from normal and cystic kidneys with Precellys

Protein fractionation from normal and cystic kidneys with Precellys

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the progressive formation of fluid-filled cysts in the kidneys, often leading to complications, including hypertension, kidney stones, urinary tract infections, and eventually kidney failure. Affecting approximately 12 million people globally, ADPKD currently has ...

ByBertin Technologies


Infection Control Resources to Mitigate Exposure Risks to Acinetobacter and Other Environmental Pathogens

Infection Control Resources to Mitigate Exposure Risks to Acinetobacter and Other Environmental Pathogens

While there are many types, the most frequent cause of infections in humans is Acinetobacter baumannii. Infections of the blood, urinary tract, and lungs, or in wounds in other parts of the body can all be caused by Acinetobacter baumannii. ...

ByCochrane & Associates, LLC


Infection Control Resources to Safeguard Patients and Building Occupants from Acinetobacter and Other Pathogens

Infection Control Resources to Safeguard Patients and Building Occupants from Acinetobacter and Other Pathogens

Those most at risk of infection according to the CDC include patients in hospitals, especially those who: · are on breathing machines · have devices such as catheters · have open wounds from surgery · are in intensive care units · have prolonged hospital stays Infections of the blood, urinary ...

ByCochrane & Associates, LLC


Infection Control Resources in Puerto Rico to Identify Acinetobacter and Other Microbial Pathogens

Infection Control Resources in Puerto Rico to Identify Acinetobacter and Other Microbial Pathogens

While there are many types, the most frequent cause of infections in humans is known as Acinetobacter baumannii. Infections of the blood, urinary tract and lungs, or in wounds in other parts of the body can all be caused by Acinetobacter baumannii. ...

ByCochrane & Associates, LLC


Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress

Common TEAEs (>5% in the zuranolone 50 mg arm) were somnolence, dizziness, sedation, headache, diarrhea, nausea, urinary tract infection and COVID-19. Sage Therapeutics and Biogen have initiated a rolling submission of a New Drug Application (NDA) to the U.S. ...

BySage Therapeutics


Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

- OXLUMO Now Indicated for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary and Plasma Oxalate Levels in Pediatric and Adult Patients - - Approval is Based on Positive Efficacy and Safety Results of the ILLUMINATE-C Phase 3 Study of OXLUMO in PH1 Patients with Severe Renal Impairment, Including Those on Hemodialysis - CAMBRIDGE, ...

ByAlnylam Pharmaceuticals, Inc.


FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

FDA Approves Taiho’s LYTGOBI® (futibatinib) Tablets for Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma

The most common (≥20%) adverse reactions were nail toxicity, musculoskeletal pain, constipation, diarrhea, fatigue, dry mouth, alopecia, stomatitis, dry skin, arthralgia, dysgeusia, abdominal pain, dry eye, nausea, decreased appetite, urinary tract infection, palmar-plantar erythrodysesthesia syndrome, and vomiting. ...

ByTaiho Oncology, Inc.


Interim results of the Expander-1 Clinical Study

Interim results of the Expander-1 Clinical Study

XFLO offers a reversible and office-based treatment option for patients who are seeking immediate relief from lower urinary tract symptoms (LUTS) caused by BPH without compromising sexual function. ...

ByProdeon Medical, Inc.


Locus Biosciences Announces $35 Million Financing

Locus Biosciences Announces $35 Million Financing

(Johnson & Johnson), proceeds from this financing will support the advancement of lead candidate LBP-EC01, a crPhage precision medicine targeting Escherichia coli (E. coli) bacteria causing urinary tract infections (UTIs), into a registrational Phase 2/3 trial, and further development of the Company’s preclinical programs focused on developing therapies ...

ByLocus Biosciences, Inc.


Etienne Jornod, Om Pharma‘S Executive Chairman Receives Swiss Biotech Success Stories Award 2022

Etienne Jornod, Om Pharma‘S Executive Chairman Receives Swiss Biotech Success Stories Award 2022

OM Pharma’s transformation will include new research and development aimed at extending the use of bacterial lysates for the prevention and treatment of a wide range of immuno-inflammatory diseases that affect millions of children and adults, including asthma, atopic dermatitis, recurrent wheezing and other diseases of the respiratory and urinary tract ...

ByOM Pharma Ltd.


The transformation of precision medicine in infectious disease

The transformation of precision medicine in infectious disease

Before Alexander Fleming discovered penicillin, another more selective antibacterial agent rose to popularity in the early 1900s: bacteriophage. In 1917, microbiologist Felix d’Herelle was tasked with identifying the cause of a dysentery outbreak impacting French troops. From his research, he noticed that Shigella bacteria was the primary culprit of this affliction. He then discovered an ...

ByLocus Biosciences, Inc.


PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP

PROCEPT Announces 5-Year WATER Study Data Comparing Aquablation to TURP

However, for men with larger prostates greater than 50 milliliters, IPSS reduction was 3.5 points greater across all follow-up visits in the Aquablation group compared to the TURP group (p=.0123). Improvement in peak urinary flow rate was 125% and 89% compared to baseline for Aquablation and TURP, respectively. ...

ByPROCEPT BioRobotics Corporation


UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients

APPROVED USE FOR JELMYTO JELMYTO® is a prescription medicine used to treat adults with a type of cancer of the lining of the upper urinary tract including the kidney called low-grade Upper Tract Urothelial Cancer (LG-UTUC). ...

ByUroGen Pharma, Inc.


UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. ...

ByUroGen Pharma, Inc.


« Back Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems

« Back Northside Healthcare System in Atlanta Advances Surgical Robotics Program with Multi-System, Multi-Hospital Agreement for PROCEPT BioRobotics AquaBeam Systems

PROCEPT designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. ...

ByPROCEPT BioRobotics Corporation


Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update

Asensus Surgical Provides Preliminary 2021 Year-End Corporate Update

According to the study, the Senhance System is a safe and feasible platform to perform multiple common urologic procedures, namely upper urinary tract and extraperitoneal radical prostatectomies. In September, a study was published which analyzed the outcomes of inguinal hernia repair procedures based on data from the Company’s TRUST registry. ...

ByAsensus Surgical US, Inc.


Why ISC Users Choose HR Lubricating Jelly for Self-Catheterization

Why ISC Users Choose HR Lubricating Jelly for Self-Catheterization

Millions of people rely on self-catheterization to empty their bladder due to conditions such as urinary bladder retention, spinal cord injury, traumatic brain injury, multiple sclerosis, and more. ...

ByHR® Pharmaceuticals, Inc.


UroGen Pharma to Present at Upcoming Conferences

UroGen Pharma to Present at Upcoming Conferences

UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. ...

ByUroGen Pharma, Inc.


First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)

UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. ...

ByUroGen Pharma, Inc.


Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring Treatment for Enlarged Prostate Symptoms

Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring Treatment for Enlarged Prostate Symptoms

Recent results from Zenflow’s pilot studies showed that at 12 months, patients displayed statistically significant symptom relief, including improved quality of life scores and increases in maximum urinary flow rates. The outcomes were recently presented at the American Urological Association 2021 annual meeting. ...

ByZenflow, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT